PT  - JOURNAL ARTICLE
AU  - Perlis, Roy H.
AU  - Green, Jon
AU  - Santillana, Mauricio
AU  - Lazer, David
AU  - Ognyanova, Katherine
AU  - Simonson, Matthew
AU  - Baum, Matthew A.
AU  - Quintana, Alexi
AU  - Chwe, Hanyu
AU  - Druckman, James
AU  - Volpe, John Della
AU  - Lin, Jennifer
TI  - Persistence of symptoms up to 10 months following acute COVID-19 illness
AID  - 10.1101/2021.03.07.21253072
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.07.21253072
4099  - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253072.short
4100  - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253072.full
AB  - Importance COVID-19 symptoms are increasingly recognized to persist among a subset of individual following acute infection, but features associated with this persistence are not well-understood.Objective We aimed to identify individual features that predicted persistence of symptoms over at least 2 months at the time of survey completion.Design: Non-probability internet survey. Participants were asked to identify features of acute illness as well as persistence of symptoms at time of study completion. We used logistic regression models to examine association between sociodemographic and clinical features and persistence of symptoms at or beyond 2 months.Setting Ten waves of a fifty-state survey between June 13, 2020 and January 13, 2021.Participants 6,211 individuals who reported symptomatic COVID-19 illness confirmed by positive test or clinician diagnosis.Exposure symptomatic COVID-19 illnessResults Among 6,211 survey respondents reporting COVID-19 illness, with a mean age of 37.8 (SD 12.2) years and 45.1% female, 73.9% white, 10.0% Black, 9.9% Hispanic, and 3.1% Asian, a total of 4946 (79.6%) had recovered within less than 2 months, while 491 (7.9%) experienced symptoms for 2 months or more. Of the full cohort, 3.4% were symptomatic for 4 months or more and 2.2% for 6 months or more. In univariate analyses, individuals with persistent symptoms on average reported greater initial severity. In logistic regression models, older age was associated with greater risk of persistence (OR 1.10, 95% CI 1.01-1.19 for each decade beyond 40); otherwise, no significant associations with persistence were identified for gender, race/ethnicity, or income. Presence of headache was significantly associated with greater likelihood of persistence (OR 1.44, 95% CI 1.11-1.86), while fever was associated with diminished likelihood of persistence (OR 0.66, 95% CI 0.53-0.83).Conclusion and Relevance A subset of individuals experience persistent symptoms from 2 to more than 10 months after acute COVID-19 illness, particularly those who recall headache and absence of fever. In light of this prevalence, strategies for predicting and managing such sequelae are needed.Trial Registration NAQuestion Which individuals are at greatest risk for post-acute sequelae of COVID-19?Findings In this non-probability internet survey, among 6,211 individuals with symptomatic COVID-19 illness, 7.9% experienced persistence of symptoms lasting 2 months or longer. Older age, but not other sociodemographic features, was associated with risk for persistence, as was headache.Meaning Identifying individuals at greater risk for symptomatic persistence may facilitate development of targeted interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThis study was supported by the National Institute of Mental Health (R01MH116270 and 1R56MH115187; Dr. Perlis) and the National Science Foundation (Dr. Ognyanova). The sponsors did not contribute to any aspect of study design, data collection, data analysis, or data interpretation. The authors had the final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was determined to be exempt by the Institutional Review Board of Harvard University; all participants signed consent online prior to survey access.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.